HemOnc Today

CURRENTLY VIEWING:

The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

PARP inhibitors take big step toward changing practice

Point/Counter

Will the use of PARP inhibitors in advanced ovarian cancer with wild-type BRCA lead to improved OS rates?

Editorial

Oncology Care Model: Progress along the learning curve

John Sweetenham, MD

Feature

NCI-sponsored clinical trials cost-effective, ‘practice influential’

Programs aim to address ‘pending and widening gap’ in palliative care workforce

Meeting News

Olaparib trial reveals ‘first personalized treatment strategy for prostate cancer’

Cabazitaxel improves outcomes among certain men with metastatic prostate cancer

Circulating tumor DNA ‘a major prognostic factor’ in colorectal cancer

Nivolumab-ipilimumab combination benefits women with advanced cervical cancer

Rivoceranib fails to significantly improve OS in advanced gastric cancer

Surgical exploration ‘highly recommended’ after induction chemotherapy for locally advanced pancreatic cancer

Ribociclib-fulvestrant combination extends OS among postmenopausal women with advanced breast cancer

Immunotherapy combination improves OS compared with chemotherapy in lung cancer subset

Tumor mutational burden does not predict efficacy of pembrolizumab, chemotherapy for advanced NSCLC

Single-agent, targeted therapies induce negligible response among smokers with NSCLC

Autoantibody blood test improves lung cancer detection

MicroRNA blood test enhances results of low-dose CT screening for lung cancer

ESMO presents awards to four clinicians

In the Journals

Pregnancy, preeclampsia linked to higher risk for transfusion reactions

Malnutrition common among older patients with cancer

Ibrutinib plus rituximab 'more effective and less toxic' than chemoimmunotherapy for chronic lymphocytic leukemia

Meeting News

Enfortumab vedotin induces responses in advanced urothelial cancer

FDA News

FDA warns breast cancer treatments may lead to rare but severe lung inflammation

FDA approves Nubeqa for prostate cancer subset

Ohio State’s cancer hospital names CEO

Radiation oncologist inducted into honorary police surgeons society